If you have been reading about Dual agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-23. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
August 19 – Jessica Bowie, a 35-year-old woman, is arrested over an alleged Islamic State-inspired terrorist attack on the New York State capital. August 20 Declaring "economic D-day," Trump announces that any nation trading with Iran will be sanctioned. Reuters reports that more than 150 Polymarket wallets may have traded using non-public U.S. military information. The Asia-based USS George Washington replaces Abraham Lincoln. August 22 The Trump administration informs Congress that it intends to pay $850 million of the several billion dollars it owes the UN, the highest payment the administration has made to the international body since demanding major reforms in exchange for ongoing support as its largest donor. 50% tariffs are imposed by the Trump administration on Canadian exports. A court in New York overturns the Trump policy of suspending the processing of immigration visas from 75 nations. Far-right activist Jake Lang, who was pardoned last year for his role in the January 6 riot at the United States Capitol, is arrested during a protest in Minneapolis, Minnesota. August 23 – The Freedom 250 Grand Prix is held at the National Mall as part of the United States Semiquincentennial celebrations. August 24 US Treasury Secretary Scott Bessent announces a new U.S. sanctions campaign against the Iranian government dubbed Operation Economic Outcast, warning that every country has a set deadline to halt economic activities with the government identified by Washington or risk Treasury action that includes the removal of the US dollar financial system.
== External links == Francium at The Periodic Table of Videos (University of Nottingham) WebElements.com – Francium Stony Brook University Physics Dept. Scerri, Eric (2013). A Tale of Seven Elements, Oxford University Press, Oxford, ISBN 9780195391312
=== Environmental impact === Metformin and its major transformation product guanylurea are present in wastewater treatment plant effluents and regularly detected in surface waters. Guanylurea concentrations above 200 μg/L have been measured in the German river Erpe, which are amongst the highest reported for pharmaceutical transformation products in aquatic environments.
Sources: en.wikipedia.org
Number of amino acid residues: 583 Molecular weight: 66,463 Da (= 66.5 kDa) isoelectric point in water at 25 °C: 4.7 Extinction coefficient of 43,824 M−1cm−1 at 279 nm Dimensions: 140 × 40 × 40 Å (prolate ellipsoid where a = b < c) pH of 1% Solution: 5.2-7 Optical Rotation: [α]259: -61°; [α]264: -63° Stokes Radius (rs): 3.48 nm Sedimentation constant, S20,W × 1013: 4.5 (monomer), 6.7 (dimer) Diffusion constant, D20,W × 10−7 cm2/s: 5.9 Partial specific volume, V20: 0.733 Intrinsic viscosity, η: 0.0413 Frictional ratio, f/f0: 1.30 Refractive index increment (578 nm) × 10−3: 1.90 Optical absorbance, A279 nm1 g/L: 0.667 ε280 = 43.824 mM−1 cm−1 Mean residue rotation, [m']233: 8443 Mean residue ellipticity: 21.1 [θ]209 nm; 20.1 [θ]222 nm Estimated a-helix, %: 54 Estimated b-form, %: 18
== Chromatography == Along with its medical applications, hydroxyapatite is also used in downstream applications under mixed-mode chromatography in polishing step. The ions present on the surface of hydroxyapatite make it an ideal candidate with unique selectivity, separation and purification of biomolecule mixtures. In mixed-mode chromatography, hydroxyapatite is used as the stationary phase in chromatography columns. The combined presence of calcium ions (C- sites) and phosphate sites (P-sites) provide metal affinity and ion exchange properties respectively. The C-sites on the surface of the resin undergo metal affinity interactions with phosphate or carboxyl groups present on the biomolecules. Concurrently, these positively charged C-sites tend to repel positively charged functional groups (e.g., amino groups) on biomolecules. P-sites undergo cationic exchange with positively charged functional groups on biomolecules. They exhibit electrostatic repulsion with negatively charged functional groups on biomolecules. For the elution of molecules buffer with high concentration of phosphate and sodium chloride is used. The nature of different charged ions on the surface of hydroxyapatite provides the framework for unique selectivity and binding of biomolecules, facilitating robust separation of biomolecules. Hydroxyapatite is available in different forms and in different sizes for the purpose of protein purification. The advantages of hydroxyapatite media are its high product stability and uniformity in various lots during its production.
=== First Trump administration (2017–2021) === On August 13, 2018, Section 1051 of the Fiscal Year 2019 John S. McCain National Defense Authorization Act (P.L. 115-232) established the National Security Commission on Artificial Intelligence "to consider the methods and means necessary to advance the development of artificial intelligence, machine learning, and associated technologies to comprehensively address the national security and defense needs of the United States." Steering on regulating security-related AI is provided by the National Security Commission on Artificial Intelligence. The Artificial Intelligence Initiative Act (S.1558) is a proposed bill that would establish a federal initiative designed to accelerate research and development on AI for, inter alia, the economic and national security of the United States. On January 7, 2019, following an Executive Order on Maintaining American Leadership in Artificial Intelligence, the White House's Office of Science and Technology Policy released a draft Guidance for Regulation of Artificial Intelligence Applications, which includes ten principles for United States agencies when deciding whether and how to regulate AI. In response, the National Institute of Standards and Technology (NIST) released a position paper, and the Defense Innovation Board issued recommendations on the ethical use of AI. A year later, the administration called for comments on regulation in another draft of its Guidance for Regulation of Artificial Intelligence Applications.
Sources: en.wikipedia.org
=== Discovery and development === The patent for Vicoprofen was filed in December 1984, and US patent number 4,587,252 was granted in May 1986. Although ibuprofen and hydrocodone were already available on the market at this time, the fact that they had never been supplied together in a single formulation required approval from the FDA as if it were a new drug. Knoll filed an investigational new drug application on 30 December 1986. A new drug application was later filed by Knoll on 25 April 1996, and received final approval from the FDA on 23 September 1997. Vicoprofen tablets were initially formulated and packaged by Knoll, with ibuprofen supplied by Albemarle Corporation and hydrocodone supplied by Mallinckrodt Pharmaceuticals. The validity of Knoll's patent on Vicoprofen has been challenged in federal court. In September 2002, the US District Court for the Northern District of Illinois granted a motion of invalidity filed by Teva Pharmaceuticals against Knoll's patent on Vicoprofen, ruling the patent was invalid as obvious. This ruling paved the way for Teva's abbreviated new drug application to be approved by the FDA which would allow them to manufacture and market their own generic. Knoll appealed the decision. In April 2003, Teva announced that its abbreviated new drug application had been approved by the FDA, and its generic would begin shipping immediately.
Neoplasm: benign or malignant Granuloma: tuberculosis Infection: round pneumonia Vascular: infarct, varix, granulomatosis with polyangiitis, rheumatoid arthritis There are a number of features that are helpful in suggesting the diagnosis:
=== Alternative lists in other Nikayas === The Kalahavivāda Sutta of the Sutta Nipāta (Sn. 862-872) has the following chain of causes (as summarized by Doug Smith):name-and-form conditions contact, contact conditions feeling, feeling conditions desire, desire conditions clinging, and clinging conditions quarrels, disputes, lamentations, and grief. Dīgha Nikāya Sutta 1, the Brahmajala Sutta, verse 3.71 describes six nidānas:
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。